A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target

Daniel M. Appledorn, Yasser A. Aldhamen, William DePas, Sergey S. Seregin, Chyong Jy J Liu, Nathan Schuldt, Darin Quach, Dionisia Quiroga, Sarah Godbehere, Igor Zlatkin, Sung Jin Kim, J. Justin McCormick, Andrea Amalfitano

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Adenoviral based vectors remain promising vaccine platforms for use against numerous pathogens, including HIV. Recent vaccine trials utilizing Adenovirus based vaccines expressing HIV antigens confirmed induction of cellular immune responses, but these responses failed to prevent HIV infections in vaccinees. This illustrates the need to develop vaccine formulations capable of generating more potent T-cell responses to HIV antigens, such as HIV-Gag, since robust immune responses to this antigen correlate with improved outcomes in long-term non-progressor HIV infected individuals. Methodology/Principal Findings: In this study we designed a novel vaccine strategy utilizing an Ad-based vector expressing a potent TLR agonist derived from Eimeria tenella as an adjuvant to improve immune responses from a [E1-]Adbased HIV-Gag vaccine. Our results confirm that expression of rEA elicits significantly increased TLR mediated innate immune responses as measured by the influx of plasma cytokines and chemokines, and activation of innate immune responding cells. Furthermore, our data show that the quantity and quality of HIV-Gag specific CD8+ and CD8- T-cell responses were significantly improved when coupled with rEA expression. These responses also correlated with a significantly increased number of HIV-Gag derived epitopes being recognized by host T cells. Finally, functional assays confirmed that rEA expression significantly improved antigen specific CTL responses, in vivo. Moreover, we show that these improved responses were dependent upon improved TLR pathway interactions. Conclusion/Significance: The data presented in this study illustrate the potential utility of Ad-based vectors expressing TLR agonists to improve clinical outcomes dependent upon induction of robust, antigen specific immune responses.

Original languageEnglish (US)
Article numbere9579
JournalPLoS One
Volume5
Issue number3
DOIs
StatePublished - Mar 8 2010
Externally publishedYes

Fingerprint

Adenovirus Vaccines
Eimeria tenella
vector vaccines
Adenoviridae
Cellular Immunity
cell-mediated immunity
agonists
Vaccines
HIV Antigens
HIV
T-cells
vaccines
antigens
Histocompatibility Antigens Class II
T-Lymphocytes
HIV Long-Term Survivors
Antigens
T-lymphocytes
immune response
AIDS Vaccines

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Appledorn, D. M., Aldhamen, Y. A., DePas, W., Seregin, S. S., Liu, C. J. J., Schuldt, N., ... Amalfitano, A. (2010). A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target. PLoS One, 5(3), [e9579]. https://doi.org/10.1371/journal.pone.0009579

A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target. / Appledorn, Daniel M.; Aldhamen, Yasser A.; DePas, William; Seregin, Sergey S.; Liu, Chyong Jy J; Schuldt, Nathan; Quach, Darin; Quiroga, Dionisia; Godbehere, Sarah; Zlatkin, Igor; Kim, Sung Jin; McCormick, J. Justin; Amalfitano, Andrea.

In: PLoS One, Vol. 5, No. 3, e9579, 08.03.2010.

Research output: Contribution to journalArticle

Appledorn, DM, Aldhamen, YA, DePas, W, Seregin, SS, Liu, CJJ, Schuldt, N, Quach, D, Quiroga, D, Godbehere, S, Zlatkin, I, Kim, SJ, McCormick, JJ & Amalfitano, A 2010, 'A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target', PLoS One, vol. 5, no. 3, e9579. https://doi.org/10.1371/journal.pone.0009579
Appledorn, Daniel M. ; Aldhamen, Yasser A. ; DePas, William ; Seregin, Sergey S. ; Liu, Chyong Jy J ; Schuldt, Nathan ; Quach, Darin ; Quiroga, Dionisia ; Godbehere, Sarah ; Zlatkin, Igor ; Kim, Sung Jin ; McCormick, J. Justin ; Amalfitano, Andrea. / A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target. In: PLoS One. 2010 ; Vol. 5, No. 3.
@article{76e4270c7a074a2bb8688d937cf7d998,
title = "A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target",
abstract = "Background: Adenoviral based vectors remain promising vaccine platforms for use against numerous pathogens, including HIV. Recent vaccine trials utilizing Adenovirus based vaccines expressing HIV antigens confirmed induction of cellular immune responses, but these responses failed to prevent HIV infections in vaccinees. This illustrates the need to develop vaccine formulations capable of generating more potent T-cell responses to HIV antigens, such as HIV-Gag, since robust immune responses to this antigen correlate with improved outcomes in long-term non-progressor HIV infected individuals. Methodology/Principal Findings: In this study we designed a novel vaccine strategy utilizing an Ad-based vector expressing a potent TLR agonist derived from Eimeria tenella as an adjuvant to improve immune responses from a [E1-]Adbased HIV-Gag vaccine. Our results confirm that expression of rEA elicits significantly increased TLR mediated innate immune responses as measured by the influx of plasma cytokines and chemokines, and activation of innate immune responding cells. Furthermore, our data show that the quantity and quality of HIV-Gag specific CD8+ and CD8- T-cell responses were significantly improved when coupled with rEA expression. These responses also correlated with a significantly increased number of HIV-Gag derived epitopes being recognized by host T cells. Finally, functional assays confirmed that rEA expression significantly improved antigen specific CTL responses, in vivo. Moreover, we show that these improved responses were dependent upon improved TLR pathway interactions. Conclusion/Significance: The data presented in this study illustrate the potential utility of Ad-based vectors expressing TLR agonists to improve clinical outcomes dependent upon induction of robust, antigen specific immune responses.",
author = "Appledorn, {Daniel M.} and Aldhamen, {Yasser A.} and William DePas and Seregin, {Sergey S.} and Liu, {Chyong Jy J} and Nathan Schuldt and Darin Quach and Dionisia Quiroga and Sarah Godbehere and Igor Zlatkin and Kim, {Sung Jin} and McCormick, {J. Justin} and Andrea Amalfitano",
year = "2010",
month = "3",
day = "8",
doi = "10.1371/journal.pone.0009579",
language = "English (US)",
volume = "5",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target

AU - Appledorn, Daniel M.

AU - Aldhamen, Yasser A.

AU - DePas, William

AU - Seregin, Sergey S.

AU - Liu, Chyong Jy J

AU - Schuldt, Nathan

AU - Quach, Darin

AU - Quiroga, Dionisia

AU - Godbehere, Sarah

AU - Zlatkin, Igor

AU - Kim, Sung Jin

AU - McCormick, J. Justin

AU - Amalfitano, Andrea

PY - 2010/3/8

Y1 - 2010/3/8

N2 - Background: Adenoviral based vectors remain promising vaccine platforms for use against numerous pathogens, including HIV. Recent vaccine trials utilizing Adenovirus based vaccines expressing HIV antigens confirmed induction of cellular immune responses, but these responses failed to prevent HIV infections in vaccinees. This illustrates the need to develop vaccine formulations capable of generating more potent T-cell responses to HIV antigens, such as HIV-Gag, since robust immune responses to this antigen correlate with improved outcomes in long-term non-progressor HIV infected individuals. Methodology/Principal Findings: In this study we designed a novel vaccine strategy utilizing an Ad-based vector expressing a potent TLR agonist derived from Eimeria tenella as an adjuvant to improve immune responses from a [E1-]Adbased HIV-Gag vaccine. Our results confirm that expression of rEA elicits significantly increased TLR mediated innate immune responses as measured by the influx of plasma cytokines and chemokines, and activation of innate immune responding cells. Furthermore, our data show that the quantity and quality of HIV-Gag specific CD8+ and CD8- T-cell responses were significantly improved when coupled with rEA expression. These responses also correlated with a significantly increased number of HIV-Gag derived epitopes being recognized by host T cells. Finally, functional assays confirmed that rEA expression significantly improved antigen specific CTL responses, in vivo. Moreover, we show that these improved responses were dependent upon improved TLR pathway interactions. Conclusion/Significance: The data presented in this study illustrate the potential utility of Ad-based vectors expressing TLR agonists to improve clinical outcomes dependent upon induction of robust, antigen specific immune responses.

AB - Background: Adenoviral based vectors remain promising vaccine platforms for use against numerous pathogens, including HIV. Recent vaccine trials utilizing Adenovirus based vaccines expressing HIV antigens confirmed induction of cellular immune responses, but these responses failed to prevent HIV infections in vaccinees. This illustrates the need to develop vaccine formulations capable of generating more potent T-cell responses to HIV antigens, such as HIV-Gag, since robust immune responses to this antigen correlate with improved outcomes in long-term non-progressor HIV infected individuals. Methodology/Principal Findings: In this study we designed a novel vaccine strategy utilizing an Ad-based vector expressing a potent TLR agonist derived from Eimeria tenella as an adjuvant to improve immune responses from a [E1-]Adbased HIV-Gag vaccine. Our results confirm that expression of rEA elicits significantly increased TLR mediated innate immune responses as measured by the influx of plasma cytokines and chemokines, and activation of innate immune responding cells. Furthermore, our data show that the quantity and quality of HIV-Gag specific CD8+ and CD8- T-cell responses were significantly improved when coupled with rEA expression. These responses also correlated with a significantly increased number of HIV-Gag derived epitopes being recognized by host T cells. Finally, functional assays confirmed that rEA expression significantly improved antigen specific CTL responses, in vivo. Moreover, we show that these improved responses were dependent upon improved TLR pathway interactions. Conclusion/Significance: The data presented in this study illustrate the potential utility of Ad-based vectors expressing TLR agonists to improve clinical outcomes dependent upon induction of robust, antigen specific immune responses.

UR - http://www.scopus.com/inward/record.url?scp=77949660661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949660661&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0009579

DO - 10.1371/journal.pone.0009579

M3 - Article

VL - 5

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 3

M1 - e9579

ER -